Updated: Verve plans first in-human base editing trial in the US after FDA lifts clinical hold

Verve Ther­a­peu­tics is plan­ning to be­gin an in-hu­man base edit­ing tri­al in the US in pa­tients with het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia (HeFH) af­ter the FDA lift­ed a clin­i­cal hold on the com­pa­ny’s IND ap­pli­ca­tion.

Verve an­nounced Mon­day that it can now ex­pand its Phase Ib clin­i­cal tri­al in­to the US. The reg­u­la­tor had placed a hold on the IND for VERVE-101 in No­vem­ber of last year, with asks for ad­di­tion­al pre­clin­i­cal and clin­i­cal da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.